Jiangsu Yuyue Medical Equipment & Supply (002223) H1 2024 earnings summary

Executive summary

• Revenue for H1 2024 was ¥4.31 billion, down 13.50% year-over-year due to normalization after a high base in the prior year.

• Net profit attributable to shareholders was ¥1.12 billion, a 25.02% decrease year-over-year.

• Cash flow from operating activities was ¥1.01 billion, down 32.42% year-over-year.

• The company maintained a strong financial position with total assets of ¥15.62 billion and a low debt ratio.

• Proposed interim dividend: ¥4 per 10 shares, with a payout ratio of 35.78%.

Financial highlights

• Gross margin was 50.06% for H1 2024.

• Basic and diluted EPS were both ¥1.1244, down 25.27% year-over-year.

• Net assets attributable to shareholders increased 2.89% from year-end 2023.

• R&D expenses were ¥270 million, accounting for 6.26% of revenue.

• Cash and equivalents at period-end were ¥6.55 billion.

Outlook and guidance

• The company expects continued growth in core segments such as respiratory, diabetes care, and infection control, with ongoing investment in innovation and international expansion.

• Management remains focused on cost control, risk management, and strengthening its competitive position in both domestic and overseas markets.